Insurers balk at Trump’s plan to cover obesity drugs in Medicare
Health insurers are raising questions about the Trump administration’s plan to cover obesity drugs in Medicare next year.
Pharmaceutical
Judge postpones OxyContin-maker Purdue Pharma’s sentencing to let opioid victims attend in person
The judge had been expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the U.S. government.
Purdue Pharma to be sentenced in criminal opioids case, allowing settlement money to flow
The criminal sentence Tuesday will mark a major step toward the company finalizing a settlement of thousands of lawsuits it faces over the toll of opioids.
UPDATE: Eli Lilly acquiring Boston-based biotech in deal worth up to $7B
Lilly has been bringing in record revenue from its weight-loss medicines, but continues to diversify its pipeline candidates through acquisitions of biotech companies that are developing new genetic therapies for cancer and other disorders.
What is ‘Ozempic personality’ and why does it make life feel ‘meh’?
The new class of GLP-1 drugs are generally considered safe. Their metabolic effects have been scrutinized in studies, but their psychological impact is far less understood.
Telix Pharmaceuticals to collaborate with Regeneron on cancer therapies
Through the collaboration, Telix and Regeneron expect to develop and commercialize next-generation radiopharmaceutical therapies targeting cancer.
Trump unveils 100% tariff on some patented drugs on ‘Liberation Day’ anniversary
Trump wrote that he deemed such actions necessary “to address the threatened impairment of the national security posed by imports of pharmaceuticals and pharmaceutical ingredients.”
FDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity
The daily oral medication, which will be branded as Foundayo, is expected to begin shipping Monday.
Novo Nordisk to cut 400 jobs in Bloomington
The drugmaker called the move a “difficult decision” but did not provide a reason for the cuts.
Lilly to acquire UK-based pharmaceutical company in deal worth up to $7.8B
Centessa Pharmaceuticals is developing treatments to address daytime sleepiness and other neurological conditions.
Obesity drug trials complicated by placebo patients leaving early
The companies developing new weight-loss medicines have a problem: People who don’t lose weight quickly figure out they were assigned to take a placebo and are bailing out of their clinical trials.
Lilly’s experimental diabetes shot yields record weight loss in study
The late-stage results handily beat earlier trials of the company’s diabetes blockbuster Mounjaro, which racked up sales of $23 billion in 2025.
Lilly spending $1.8B to update Indianapolis manufacturing operations
The Lilly Technology Center investment includes expanding existing capabilities and the establishment of new production lines.
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers after an agreement that will see Novo Nordisk’s branded weight loss medicines sold through the Hims platform.
Chief technology officer spent whole career at Lilly
Tim Coleman has held positions within information technology at Lilly in research and development, sales and marketing, manufacturing, and human resources.
Generic Ozempic could cost less than $3 a month, study shows
Generic Ozempic is set to emerge in major markets from India and Brazil to China and Canada this year, reshaping the sector in those countries.
GLP-1 fight plays out in statehouses, courthouses
While major drugmakers tussle for market supremacy, they are also taking on compound pharmacies that have not stopped selling obesity drugs despite the end of the shortage of such drugs.
FDA declines to review Moderna application for first mRNA-based flu vaccine
Moderna President Stephen Hoge said that the company had previously engaged with the FDA on the trial design and that the agency had indicated it would be acceptable.
Novo Nordisk vows to sue after Hims & Hers launches Wegovy knockoff pill
Shares in Indianapolis-based Eli Lilly and Co., a rival to Novo Nordisk in the weight-loss market, also fell after the announcement, dropping 7.8% Thursday.
Trump administration to launch TrumpRx website for discounted drugs
The president first teased TrumpRx in September while announcing the first of his more than 15 deals with pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., to lower drug prices.